Many studies showed that GLP-1 RA in vitro can inhibit the inflammation and modulate immune response [38,39,40,41,42]
Why Your Injection Site Matters GLP-1 receptor agonists are designed for subcutaneous delivery, meaning they need to be injected into the fat layer just beneath the skin
In its Acceleration Plan to Stop Obesity, adopted in 2022, WHO highlights many different factors contribute to obesity and that the matter is not just a matter of individual responsibility
Bone health is also a concern, especially for women in menopause who are already at risk for bone loss
The report further distinguished clinical obesity, defined as excess adiposity with significant tissue or organ dysfunction that can lead to severe complications, from preclinical obesity, defined as excess adiposity without immediate organ dysfunction but with an increased risk of progression to clinical obesity and other non-communicable diseases
Improving nutrition, physical activity and other healthy lifestyle habits benefits almost everyone, but not everyone needs to focus specifically on GLP-1
